In July 18th, the United States Centrexion pharmaceutical company executive vice president and chief medical officer Stevens Kerrie and director of Commerce Brady Randall visit to Shanghai new exploration company. Yin Qingyuan, general manager of the new exploration company, Zhang Yunrong, director of Excellence Center, Ceng Fanxin, director of the Department of medicine, Fan Pengcheng, director of the Department of medicine and the Department of medicine project manager received a visiting guest.

Zhang Yunrong first introduced the general situation of Haike group and new exploration, Yin Qingyuan describes the status of the strategic direction of the transformation and new exploration of Shanghai Haike group in Haike group in transition, Ceng Fanxin is the strategic direction of the Shanghai pharmaceutical investment, as well as new exploration of why pain management as a key investment field to answer the Brady question. Then, the mechanism of the potential cooperation projects of Centrexion pharmaceuticals, clinical efficacy and safety of such problems are discussed, and the possible cooperation between the two sides of communication and discussion mode. The two sides agreed to continue to maintain communication and follow-up after the meeting, the new exploration of the project and the value of Centrexion pharmaceutical companies to re evaluate, so as to determine the possibility of cooperation and cooperation model.

The Centrexion is a pharmaceutical company focused on pain management drug development company, the current drug in the treatment of pain of osteoarthritis undergoing phase II clinical trials, and 4 new projects at an early stage. Centrexion pharmaceutical company is seeking strategic partners in the world to support its project development and the company's IPO program.

Shanghai new company as the core of enterprise strategic transformation bear Haike group, founded in December 2015. Has been in the new materials, specialty chemicals and pharmaceutical industry to expand the layout of new business. In the field of medicine, new exploration company focused on the layout of the direction of the investment is pain management, autoimmune diseases, central nervous system diseases and tumors, and has been in the field of pain management to achieve the introduction of 1 projects.